Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 60 for your search:
Drug:
letrozole
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Aromatase Inhibitor Clinical Trial
Phase:
Phase IV
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
40 to 70
Sponsor:
NIGMS
Protocol IDs:
0412-14
, UO1-GM61373-06, NCT00228956
2.
Assessment of Quality of Life, Bone Density and Safety in Postmenopausal Breast Cancer Patients With Letrozole Therapy
Phase:
Phase IV
Type:
Supportive care, Treatment
Status:
Active
Age:
45 and over
Sponsor:
Other
Protocol IDs:
KBCSG002
, NCT00913016
3.
Phase II/III Randomized Study of Neoadjuvant Therapy Comprising Exemestane Versus Letrozole Versus Anastrozole in Postmenopausal Women With Estrogen Receptor Positive Stage II or III Breast Cancer
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
Postmenopausal
Sponsor:
NCI
Protocol IDs:
ACOSOG-Z1031
, CALGB-ACOSOG-Z1031, SDC1, NCT00265759
4.
Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
Postmenopausal
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CZOL446GDE19
, NCT00375752
5.
Second-Line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
not specified
Sponsor:
Other
Protocol IDs:
N07MAN
, Eudract 2007-007030-20, NCT00684216
6.
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
65 and over
Sponsor:
Other
Protocol IDs:
0120070323
, NCT00698971
7.
Phase III Randomized Study of Letrozole Versus Placebo in Postmenopausal Women With Primary Breast Cancer Who Have Completed at Least Five Years of Adjuvant Aromatase Inhibitor
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Postmenopausal
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
CAN-NCIC-MA17
, CALGB-49805, E-JMA17, EORTC-10983, IBCSG-BIG97-01, NCCTG-JMA17, SWOG-JMA17, JRF-Vor-Int-10, NCCTG-CAN-MA17, SWOG-CAN-MA17, NCT00003140, JMA17, MA17
8.
Phase III Randomized Study of Letrozole With or Without Lapatinib Ditosylate in Postmenopausal Women With Stage IV Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
GSK-EGF30008
, UCLA-0311034-01, NCT00073528
9.
Assessing Impact of Loco-Regional Treatment on Survival in Metastatic Breast Cancer at Presentation
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
21 to 65
Sponsor:
Other
Protocol IDs:
TMH/153/2004
, NCT00193778
10.
Phase III Randomized Study of Adjuvant Combination Chemotherapy and Hormonal Therapy Versus Adjuvant Hormonal Therapy Alone in Women With Previously Resected Axillary Node-Negative Breast Cancer With Various Levels of Risk for Recurrence (TAILORx Trial)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
NCI
Protocol IDs:
ECOG-PACCT-1
, SWOG-ECOG-PACCT-1, CALGB-ECOG-PACCT-1, NCCTG-ECOG-PACCT-1, NSABP-ECOG-PACCT-1, ACOSOG-ECOG-PACCT-1, CAN-NCIC-MAC12, PACCT-1, NCT00310180, TAILORx
11.
Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
Phase:
Phase III
Type:
Supportive care
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CFEM345DDE09
, NCT00332709
12.
Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CFEM345DDE10
, NCT00332852
13.
Phase III Randomized Study of Letrozole in Postmenopausal Women With Hormone Receptor-Positive Breast Cancer Who Have Completed Adjuvant Hormonal Therapy Comprising An Aromatase Inhibitor and/or Tamoxifen Citrate
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Any age (postmenopausal)
Sponsor:
NCI
Protocol IDs:
NSABP-B-42
, NCT00382070
14.
Phase III Randomized Study of Chemotherapy and Endocrine Therapy as First-Line Treatment for Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 75
Sponsor:
Other
Protocol IDs:
KRDI-TUM-CORE-GYN-040-380-21260
, EU-20660, EUDRACT-2005-000986-20, KRDI-TUM-COR-259-PAE-0100-I, NCT00403182
15.
Phase III Randomized Study of 70-Gene Signature Versus Clinical Assessment in Selecting Women With Node-Negative Breast Cancer for Adjuvant Chemotherapy
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
EORTC-10041
, EUDRACT-2005-002625-31, BIG-3-04, NOVARTIS-EORTC-10041, ROCHE-EORTC-10041, SANOFI-AVENTIS-EORTC-10041, NCT00433589
16.
HOBOE: A Study of Hormonal Adjuvant Treatment Effect on Bone Mineral Density in Early Breast Cancer Patients
Phase:
Phase III
Type:
Supportive care
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
HOBOE
, NCT00412022
17.
Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer
Phase:
Phase III
Type:
Behavioral study, Supportive care, Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
OCOG-2007-LISA
, NCT00463489
18.
Phase III Randomized Study of Adjuvant Therapy Comprising Tamoxifen Citrate Followed By Either Anastrozole, Letrozole, or Exemestane Versus Anastrozole, Letrozole, or Exemestane Alone in Postmenopausal Women With Resected Endocrine-Responsive Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
Other
Protocol IDs:
GIM-3-FATA
, GIM3-FATA, EUDRACT-2006-004018-42, EU-20764, NCT00541086
19.
Phase III Randomized Study of Continuous Letrozole Versus Intermittent Letrozole in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive, Early-Stage Breast Cancer After Completion of 4 to 6 Years of Prior Adjuvant Endocrine Therapy
Phase:
Phase III
Type:
Prevention
Status:
Active
Age:
Postmenopausal
Sponsor:
Other
Protocol IDs:
IBCSG-35-07
, IBCSG-35-07, BIG-1-07-SOLE, EUDRACT-2007-001370-88, NCT00553410
20.
BEVACIZUMAB + LETROZOL vs LETROZOL as First Line Treatment in Postmenopausal Patients With Advanced or Metastatic Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 80
Sponsor:
Other
Protocol IDs:
GEICAM/2006-11
, Nº EudraCT: 2007-002841-19, NCT00545077
21.
Phase III Randomized Study of Tamoxifen Citrate or Letrozole With Versus Without Bevacizumab in Women With Hormone Receptor-Positive Stage IIIB-IV Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CALGB-40503
, CALGB 40503, NCT00601900
22.
Phase III Randomized Study of Letrozole in Preventing Breast Cancer in Postmenopausal Women With the BRCA1/BRCA2 Mutation
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Prevention
Status:
Active
Age:
40 to 69
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
FNCLCC-ONCO-03/0701
, FNCLCC-ONCO 03/0701 - LIBER, EU-20806, NOVARTIS-FNCLCC-ONCO 03/0701, NCT00673335
23.
Phase III Randomized Study of Fulvestrant With or Without Lapatinib Tosylate and/or Aromatase Inhibitor Therapy in Postmenopausal Women With Metastatic Breast Cancer That Progressed After Prior Aromatase Inhibitor Therapy
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
GIM-GIM8-OVER
, GIM8-OVER, EUDRACT-2007-006031-30, EU-20853, GSK-GIM-GIM8-OVER, ZENECA-GIM-GIM8-OVER, OVER, NCT00688194
24.
Phase III Randomized Study of Letrozole in Women With Primary Breast Cancer Who Have Received 5 Years of Adjuvant Aromatase Inhibitor Therapy
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
CAN-NCIC-MA17R
, MA17R, NCT00754845
25.
Phase III Randomized Study of Adjuvant Endocrine Therapy Comprising Letrozole, Anastrazole, or Exemestane Versus Tamoxifen Citrate in Postmenopausal Women With Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 70
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
COL-MNEMOSYNE
, MNEMOSYNE, 2007-12, INCA-RECF0899, EUDRACT-2008-003620-32, NCT00893061
Select All on Page
1
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
